{"SPADE_N_00048": {"Clinical Information": [], "Patent Information": [{"Patent No": "US 2023/0416797 A1", "Patent Link": "http://www.lens.org/lens/patent/US_2023_0416797_A1", "Patent Type": "Patent Application", "Publication Date": "2023-12-28", "Family Info": "JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1", "Patent Title": "MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE", "Abstract": "Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described."}], "Sequence Information": {"SPADE ID": "SPADE_N_00048", "Peptide Name": "Bacteriocin duramycin (Leucopeptin; Bacteriocin)", "Source": "Streptoverticillium griseoverticillatum (Gram-positive bacteria)", "Family": "Belongs to the type B lantibiotic family (Class I bacteriocin)", "Gene": "Not found", "Sequence": "CKQSCSFGPFTFVCDGNTK", "Sequence Length": 19, "UniProt Entry": ["http://www.uniprot.org/uniprot/P36504"], "Protein Existence": "Protein level", "Biological Activity": ["Antimicrobial", "Antibacterial"], "Target Organism": "No MICs found in DRAMP database", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "Not included yet", "Binding Target": "phosphatidylethanolamine", "Linear/Cyclic": "Not included yet", "N-terminal Modification": "Not included yet", "C-terminal Modification": "Not included yet", "Stereochemistry": "Not included yet", "Structure Description": "Not found", "Formula": "C89H133N23O28S3", "Mass": 2069.34, "PI": 7.95, "Net Charge": 1, "Hydrophobicity": -0.19, "Half Life": "Mammalian:1.2 hourYeast:>20 hourE.coli:>10 hour", "Function": "Acts as inhibitor of human phospholipase A2.", "PTM": "Methyllanthionine rings between residues 1 and18 as well as between residues 5 and 11; a lanthionine occurs between Cys14 and residue 4. In addition, addition of Lys19 to dehydralanine at position 6 forms a lysinoalanine bridge. The Asp residue at position 15 is hydroxylated.", "Literature": [{"Title": "The structure of PA48009 the revised structure of duramycin.", "Pubmed ID": "2272918", "Reference": "J Antibiot (Tokyo). 1990 Nov;43(11)1421-1430.", "Author": "Hayashi F, Nagashima K, Terui Y, Kawamura Y, Matsumoto K, Itazaki H.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=2272918"}, {"Title": "Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin.", "Pubmed ID": "2125590", "Reference": "J Antibiot (Tokyo). 1990 Nov;43(11)1403-1412.", "Author": "Fredenhagen A, Fendrich G, Märki F, Märki W, Gruner J, Raschdorf F, Peter HH.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=2125590"}], "Frequent Amino Acids": "CFG", "Absent Amino Acids": "AEHILMORUWY", "Basic Residues": 2, "Acidic Residues": 1, "Hydrophobic Residues": 5, "Polar Residues": 12, "Positive Residues": 2, "Negative Residues": 1, "Similar Sequences": [{"SPADE_ID": "SPADE_N_15396", "Similarity": 1.0, "Sequence": "CKQSCFGPFTFVCGNTK"}, {"SPADE_ID": "SPADE_N_00050", "Similarity": 0.9473684210526315, "Sequence": "CRQSCSFGPFTFVCDGNTK"}, {"SPADE_ID": "SPADE_N_06055", "Similarity": 0.9473684210526315, "Sequence": "MTASILQQSVVDADFRAALLENPAAFGASAAALPTPVEAQDQASLDFWTKDIAATEAFACRQSCSFGPFTFVCDGNTK"}]}}}